TG Therapeutics ( (TGTX) ) has released its Q1 earnings. Here is a breakdown of the information TG Therapeutics presented to its investors.
TG Therapeutics is a commercial stage biopharmaceutical company focused on developing and commercializing novel treatments for B-cell diseases, with a particular emphasis on multiple sclerosis. The company has received approval for BRIUMVI, a treatment for relapsing forms of multiple sclerosis, in the U.S. and several European countries.
In its latest earnings report, TG Therapeutics announced a strong start to 2025 with first quarter U.S. net revenue from BRIUMVI reaching $119.7 million, marking a 137% increase from the previous year. The company has also raised its full-year revenue guidance for BRIUMVI in the U.S. to approximately $560 million and its global revenue target to $575 million.
Key financial highlights include a significant increase in product revenue, driven by the successful commercialization of BRIUMVI. The company reported a net income of $5.1 million for the first quarter of 2025, a notable improvement from a net loss of $10.7 million in the same period last year. Additionally, TG Therapeutics is advancing its pipeline with ongoing clinical trials for subcutaneous BRIUMVI and other treatments.
Looking ahead, TG Therapeutics remains optimistic about its growth prospects, with plans to continue expanding BRIUMVI’s market presence and advancing its development pipeline. The company aims to achieve its long-term goal of making BRIUMVI the leading anti-CD20 treatment based on market share, while also focusing on innovation and improving treatment options for patients with multiple sclerosis.